Melatonin and High Blood Pressure: Who Might Benefit, Why, and How to Use It Safely with Your Usual Treatment

Why Melatonin Comes Up in Hypertension Care

Melatonin is the pineal gland's "darkness signal," synchronizing sleep and the broader circadian system. Blood pressure has its own daily rhythm: in healthy dippers, BP falls 10–20% during sleep relative to daytime values. A substantial minority of hypertensive patients do not show this fall — non-dippers — and some even run higher at night than during the day — reverse dippers. Both patterns are independently associated with greater risk of left ventricular hypertrophy, stroke, and chronic kidney disease, largely because nighttime BP burden correlates more tightly with target-organ damage than office or daytime readings do.

Melatonin's proposed influence on this rhythm operates through three overlapping mechanisms:

• Central: acting on MT1/MT2 receptors in the suprachiasmatic nucleus to dampen nighttime sympathetic outflow.
• Vascular: direct effects on vascular melatonin receptors that support endothelial function and reduce oxidative stress (via inhibition of myeloperoxidase activity), which may lower peripheral resistance overnight.
• Behavioral: better sleep continuity, which secondarily reduces the BP-raising effect of nocturnal arousals.

These effects are real in trial data but modest, formulation-dependent, and inconsistent across studies — melatonin is an adjunct that supports circadian and sleep physiology, not a substitute for guideline-directed antihypertensive therapy.

What the Evidence Actually Shows

The foundational evidence is a 2011 meta-analysis of seven randomized, placebo-controlled trials (221 subjects) using 24-hour ambulatory BP monitoring. Pooling all seven trials together, melatonin did not significantly reduce nocturnal BP (systolic −2.3 mmHg, 95% CI −6.9 to 2.5; diastolic −1.4 mmHg, 95% CI −4.0 to 1.3). The signal only emerged on subgroup analysis: controlled-release (CR) melatonin, 2–3 mg, significantly reduced nocturnal systolic BP by 6.1 mmHg (95% CI −10.7 to −1.5) and diastolic BP by 3.5 mmHg (95% CI −6.1 to −0.9), while fast-release melatonin (5 mg) had essentially no effect (systolic −0.3 mmHg, diastolic −0.2 mmHg). This is the source of the often-cited "3–6 mmHg" figure, and it's important to represent it honestly: it comes from a small subgroup (106 data points across three trials), not from the meta-analysis as a whole.

Individual trials add texture to this. A crossover study in men with essential hypertension found repeated bedtime CR-melatonin reduced nocturnal systolic/diastolic BP by about 6/4 mmHg without changing heart rate. A separate trial in patients with confirmed nocturnal hypertension found 2 mg CR-melatonin over four weeks reduced nocturnal systolic BP from 136±9 to 130±10 mmHg, with the largest effect between 2 a.m. and 5 a.m. Conversely, a crossover trial using high-dose (24 mg) sustained-release melatonin in African-American patients found no nocturnal BP reduction at all, underscoring that dose, formulation, and population all modify the response.

On the beta-blocker question, a placebo-controlled trial in hypertensive patients treated with beta-blockers found that three weeks of nightly melatonin significantly improved sleep quality and sleep maintenance, without tolerance developing and without rebound insomnia after stopping. Beta-blockers suppress nocturnal melatonin secretion by blocking the beta-adrenergic signal that normally drives pineal melatonin synthesis, which is the physiological rationale for replacing it exogenously.

Who Might Reasonably Try It

Insomnia with confirmed nocturnal hypertension or non-dipping. This is the best-supported scenario. Ideally, non-dipping or nocturnal hypertension should be confirmed by ambulatory blood pressure monitoring (ABPM) rather than assumed, since home morning/evening cuff readings can miss the pattern.

Hypertension on beta-blockers with sleep disturbance. Given the mechanistic link between beta-blockade and suppressed endogenous melatonin, this group has the clearest rationale and trial support for melatonin improving both sleep and nighttime BP.

Shift work, jet lag, or irregular schedules. Circadian misalignment blunts nocturnal dipping. Melatonin's evidence here is mostly extrapolated from sleep-timing studies rather than dedicated BP outcome trials, so expectations should be modest.

Older adults with fragmented sleep and elevated nighttime BP. Endogenous melatonin production declines with age, and non-dipping prevalence rises. Low-dose CR-melatonin can be considered here, but this population also carries the highest risk of falls and orthostatic symptoms, so it warrants closer monitoring, not looser criteria.

Who Should Be Cautious or Avoid It

Heart failure or high cardiovascular risk. This is the most important recent update. A large observational study presented at the American Heart Association's 2025 Scientific Sessions used the TriNetX global database to compare 65,414 adults with chronic insomnia who had used melatonin for 12+ months against an equal number of propensity-matched non-users (patients with pre-existing heart failure were excluded from both groups at baseline). Over five years:

Outcome	Melatonin users	Matched controls	Hazard ratio
Incident heart failure	5% (3,021)	3% (1,797)	1.89
HF hospitalization	19% (12,411)	7% (4,309)	~3.5
All-cause mortality	8% (5,118)	4% (2,820)	2.09

The association held in a sensitivity analysis restricted to people with two or more melatonin prescriptions filled 90+ days apart (HR for incident HF 1.82). This is a retrospective, propensity-matched cohort — not a randomized trial — so it cannot establish causation, and the study's own authors and outside cardiologists have emphasized that residual confounding (e.g., unmeasured severity of insomnia or subclinical cardiac disease driving both melatonin use and HF risk) remains possible. Still, given that pre-existing HF patients were excluded and the effect size was large and consistent across three related outcomes, this is a genuine safety signal that changes the risk-benefit calculation for long-term, high-dose melatonin use in anyone with elevated cardiovascular risk — not just those with diagnosed HF.

Advanced chronic kidney disease. Data in stage 4–5 CKD and dialysis patients are limited; involve nephrology before starting.

Concurrent sedatives, opioids, or alcohol. Additive sedation and fall risk.

Pregnancy and breastfeeding. Insufficient safety data; avoid unless specifically directed by an obstetrician.

Autoimmune disease or immunosuppressive therapy. Melatonin has immune-modulating properties and should only be used under supervision in this context.

Integrating Melatonin with Standard Antihypertensive Care

Keep your prescribed regimen unchanged. Melatonin is additive, not substitutive. ACE inhibitors, ARBs, calcium-channel blockers, diuretics, and beta-blockers should continue exactly as prescribed.

Formulation matters more than almost anything else. The trial evidence for nocturnal BP benefit is essentially confined to controlled/prolonged-release melatonin; immediate-release formulations act mainly on sleep onset and have not shown a consistent BP effect .

Typical study doses were 2–5 mg at bedtime, with most positive nocturnal-BP trials using 2–3 mg CR-melatonin. Higher is not necessarily better — the 24 mg sustained-release trial in African-American patients showed no BP benefit despite the higher dose. Start at the lowest effective dose (2 mg) and reassess before increasing.

Timing: 30–60 minutes before intended bedtime, in dim light, avoiding bright screens afterward to support the circadian signal rather than just the sedative effect.

Monitoring:

• Home BP morning and evening; bedtime and on-waking readings add useful information if feasible.
• ABPM before and 4–8 weeks after starting is the most rigorous way to confirm whether dipping status or nocturnal BP actually changed — subjective sleep improvement doesn't guarantee a BP effect.
• Watch specifically for excessive nocturnal BP lowering: dizziness on nighttime standing, syncope, or falls, particularly in patients already on two or more antihypertensives.

Interactions to flag with your clinician:

• Beta-blockers: mechanistically complementary (replacing suppressed endogenous melatonin) but theoretically additive on bradycardia/hypotension in sensitive patients.
• Calcium-channel blockers: some data suggest melatonin may potentiate their BP-lowering effect, raising hypotension risk; one older study actually reported a paradoxical BP and heart-rate increase when melatonin was added to nifedipine GITS, illustrating that the interaction direction isn't fully predictable.
• Anticoagulants/antiplatelets: scattered reports of altered bleeding risk; discuss if on warfarin, DOACs, or dual antiplatelet therapy.
• Other sedatives: compounded daytime sedation, confusion, and fall risk.

A Practical Step-by-Step Plan

1. Confirm the indication first. Without documented insomnia, non-dipping, nocturnal hypertension, or beta-blocker-associated sleep disruption, melatonin is unlikely to add meaningful BP benefit — don't start it as a generic "heart-healthy" supplement.
2. Review risk factors with your clinician, specifically heart failure history or risk, kidney function, current medication list, and fall risk, given the 2025 HF signal.
3. Start low: 2 mg controlled-release, 30–60 minutes before bedtime.
4. Track both sleep and BP for 1–2 weeks: time to bed, sleep latency, awakenings, total sleep time; morning/evening (and ideally bedtime/waking) BP; any dizziness or daytime sedation.
5. Reassess at 4–8 weeks. Continue only at the lowest effective dose if there's a clear, measurable benefit; if not, stop rather than continuing indefinitely on the assumption it might be helping.
6. Avoid open-ended, high-dose use without periodic review — this is now the central safety lesson from the 2025 cohort data, which specifically implicated long-term (≥12 month) use.

What Remains Uncertain

• Long-term cardiovascular safety. The 2025 TriNetX signal for heart failure and mortality is observational and needs replication in prospective, adjudicated studies before it can be considered causal, but it is large, consistent across outcomes, and specific to long-duration use.
• Optimal dose, formulation, and duration for nocturnal hypertension. Most positive BP trials are small (dozens of subjects), weeks to a few months long, and use 2–3 mg CR formulations — this is a narrow evidence base to generalize from.
• Predictors of response. No validated way yet exists to identify in advance who will show a meaningful nocturnal BP reduction versus no effect.

Bottom Line

Melatonin, specifically controlled-release formulations at 2–3 mg, has reasonable trial evidence for modestly lowering nocturnal blood pressure (roughly 3–6 mmHg systolic) in selected patients with insomnia, confirmed non-dipping, nocturnal hypertension, or beta-blocker–associated sleep disruption. It is not a treatment for hypertension itself and should never replace prescribed antihypertensive therapy.

The 2025 AHA cohort data linking long-term melatonin use to nearly double the rate of incident heart failure, over three times the HF hospitalizations, and roughly double the all-cause mortality is a meaningful caution signal, even though it's observational rather than causal. This shifts the practical guidance toward short- to medium-term, low-dose, periodically reviewed use — particularly in anyone with elevated cardiovascular risk — rather than indefinite nightly supplementation. If you and your clinician decide to try it, treat melatonin as a circadian and sleep-support tool with a plausible, modest nighttime BP benefit, used under monitoring and subject to regular reassessment — not as a standalone or long-term cardiovascular therapy.

More about this topic can be found in our books on Our Books on Google Play and related articles in the Index.

Mykola Iabluchanskyi together with Andriy Yabluchanskiy